
Prostatype
Genomics
Annual report
2025

Table of contents

About Prostatype Genomics

Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Comments by Prostatype Genomics' CEO Fredrik Rickman

In 2025, Prostatype Genomics has continued to develop its business in line with its long-term strategy – to establish Prostatype® as a clinically validated and commercially scalable decision support in prostate cancer, with a particular focus on the U.S. market. In an environment that has continued to be characterized by changes in capital market conditions, our work has been consistently focused on strengthening the fundamental value drivers in the business.

The scientific evidence forms the foundation of our activities. During the year, we have further strengthened this through new published studies, including data from the U.S., which further confirms the prognostic relevance of Prostatype®. A strong and growing evidence base is crucial, not only for clinical acceptance, but also for reimbursement decisions and long-term commercial scalability.

In the U.S. market, we have taken a significant step forward in 2025 by completing the introduction phase and starting to invoice private insurance companies. This means that the use of Prostatype® is increasingly linked to established reimbursement flows, which is a central component in building a sustainable business model.

The work related to the ongoing Medicare process continues and remains strategically crucial for the company's development. An approval would significantly improve market access and create increased predictability in the reimbursement structure. At the same time, regulatory processes of this nature are complex and difficult to assess in terms of time.

In recent years, we have seen several structural transactions in the molecular diagnostics and precision medicine segment, where companies with clinically validated tests and an established presence in the U.S. have been acquired by major industrial players. In these contexts, assessments are typically based on factors such as the quality of the evidence, reimbursement opportunities, the scalability of the technology platform and the company's position in the decision-making flows of the healthcare systems. Considering this background, the company has gradually strengthened its position in several of these areas in recent years through a strengthened evidence base, establishment in the U.S. market, and the initiation of reimbursement-based clinical use.

This underlines the importance of developing the business from a long-term industrial perspective, where value creation is driven by the quality of the underlying structures rather than individual milestones. At the same time, the valuation of listed growth companies is affected by broader capital market conditions, such as access to capital, risk appetite and liquidity, factors that can vary over time and do not always reflect the long-term industrial perspective.

An important part of our continued development is the work to broaden the area of use for Prostatype®, and we have therefore taken steps towards evaluating the relevance of the test also for patients who have undergone radical treatment, with initial results that we consider to be very promising. Over time, this development can help strengthen both the clinical and commercial potential of the product.

Financially, the company has implemented measures during the year that strengthen the financial freedom of action and enable continued focus on commercialization and further development of our technology platform. At the same time, the need for additional capital remains to fully realize the company's growth ambitions, as commercial leverage requires both time and investments.



Looking ahead, our priority is clear: to continue to strengthen the evidence base, drive reimbursement processes forward and gradually increase the clinical use of Prostatype®. With the progress made during the year, and a strengthened position within our key value drivers, we are well positioned for the next phase of the company's development and to realize the long-term potential in our technology.

Finally, I would like to extend a big thank you to our employees, clinical partners and shareholders for your continued commitment and trust. Together, we have laid a solid foundation for the company's continued development, and I look forward to the coming year with confidence.

Stockholm in May 2026

Fredrik Rickman
CEO Prostatype Genomics

About the Company and the Prostatype® genetic test

Prostatype Genomics offers the gene test Prostatype® for prognostication of diagnosed prostate cancer, one of the most common cancer types affecting around one in eight men. Prostatype® is based on a patented technology to measure the expression of embryonic cancer stem cells and makes it possible to reduce the proportion of radical treatment by approx. 30-40%. By introducing Prostatype® into the healthcare chain as a supplementary decision-making basis when choosing treatment, it will be possible to significantly improve the quality of life for millions of men and at the same time reduce healthcare queues and achieve very large cost savings on both the healthcare and the society level.

There is extensive scientific support for Prostatype®, and the Company's testing service has already been launched in selected markets in Europe. However, the major sales revenue is expected to come from the United States where Prostatype® became commercially available in 2024. The Company is in the final phase of receiving approval for reimbursement from the large public healthcare insurance program Medicare of up to 3,700 USD per test.

U.S. market currently valued at 4 billion SEK – with more than twice as large market potential

Based on, among other things, sales data for 2024 from an American peer company[1], the Company estimates the current U.S. market for Prostatype® to at least 4 billion SEK (375 million USD) per year, and the U.S. market potential is estimated to at least 10 billion SEK (970 million USD). The Company aims to achieve a significant market share in the United States, with a maintained gross profit margin and an attractive industry-relevant operating margin.

The Company continuously evaluates possible collaborations or a sale of the entire Company, taking the interests of the shareholders and the patient group into account.

Prostatype® Test System

The Prostatype® system identifies the genetic fingerprint for prostate cancer by measuring information from the genes of the cancer stem cells in the tissue sample (biopsy) already obtained in connection with the patient being diagnosed. In other words, Prostatype Genomics uses the patient's original biopsy, which means that the patient in question does not need to undergo additional tests to be able to diagnose the prostate cancer while increasing the precision of the treatment decision.

Prostatype® is intended to be used as a complement to the current clinical diagnostic and prognostic methods routinely used by healthcare systems. Prostatype® is the only prostate cancer gene test that measures gene expression in embryonic cancer stem cells in prostate cancer in a format that allows independent laboratories to perform tests.

Prostatype® Genomics Test System is a package consisting of Prostatype® RTqPCR kit, patient database and algorithms, PWS (Prostatype Web System) and associated P-score.



Illustration showing where in the process Prostatype® becomes relevant during diagnosis and potential treatment of prostate cancer.

Image showing the Prostatype® packaging.

1) https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-fourth-quarter-and-full-year-2024-financial

Strong scientific support for Prostatype®

There is extensive scientific support for Prostatype® from completed studies in Sweden, Spain, Taiwan and the U.S. with their respective results published in peer-reviewed scientific journals. Together, these publications cover relevant patient groups with broad ethnicity in Europa, the U.S. and Asia. Furthermore, a unique long-term follow-up study is being conducted at Uppsala University with a follow-up period of up to 30 years.

Validation study at Skåne University Hospital

A validation study at Skåne University Hospital, with docent Göran Ahlgren as the principal investigator, showed that 36.7 percent of the patients whose prostate cancer was categorized as intermediate risk type can be recategorized to low-risk type. Around 42 percent of the patients whose prostate cancer was categorized as high-risk using the existing methods could be recategorized into low- (10.5 percent) and intermediate-risk type (31.5 percent). None of the patients whose cancer was graded with a P-score in the low or intermediate category died as a result of prostate cancer, which further strengthens the prognostic value and reliability of the P-score. These results were published in the internationally recognized peer-reviewed journal the Prostate in 2023.

Multicentre study in Spain

In a multicentre study with 93 included prostate cancer patients at 7 hospitals, coordinated by the Spanish National Association of Urology, Prostatype® showed significantly stronger prognostic performance than the comparison metrics NCCN,® D'Amico and EAU for both the risk of prostate cancer-specific mortality within 10 years and the risk of developing metastases. In the study, Prostatype® had a C-index of 0.90 compared to 0.73 for NCCN®. The test's practical utility was clearly shown as the treatment plan could have been modified for 39% of the patients if it had been used as a basis for choosing treatment plan at the time of diagnosis. The study also showed that:

- Prostatype® can predict progression, i.e. predict which patients need curative treatment immediately upon diagnosis and thus not suitable for active monitoring.

- Prostatype® confirms the cases in which it may be appropriate to postpone curative treatment for some men with low-risk prostate cancer.

Validation study in Taiwan

In a validation study in Taiwan, Prostatype® showed significant superiority in predicting prostate cancer-specific mortality compared to the guidelines of the National Comprehensive Cancer Network (NCCN®), as well as against PSA and magnetic resonance imaging (MRI). Prostatype® showed significantly stronger precision compared to NCCN® with a so-called C-index of 0.90 for Prostatype® compared to 0.73 for NCCN®. The study included 148 Taiwanese men, of which 56 had metastases at diagnosis, and the results were published in the journal BJUI Compass in mid-2025.

Long-term follow-up study at Uppsala University Hospital

A long-term follow-up study is being conducted in collaboration with Uppsala University Hospital with a follow-up period of up to 30 years, compared to up to around ten years in earlier studies. The study enables the Company to predict the risk of dying due to prostate cancer with even greater certainty in the future, and to extend the time to 15-20 years. Interim results from the study have shown a very good accuracy for Prostatype® even after a full 20 years of follow-up time after diagnosis. None of the patients analysed who were classified as low risk by Prostatype® died of their prostate cancer during up to 20 years of follow-up time. Results from the study are expected to be published in a medical journal in the second half of 2026.

This study is based on a previously completed clinical study in 2021-2022, which was completed with positive results.

Validation study in the U.S.

In a U.S. validation study with 160 included patients led by Professor Stephen Freedland of the Department of Urology at Cedars-Sinai, and in collaboration with the Durham Veterans Affairs Healthcare System, Prostatype® demonstrated impressive performance in line with what the product has shown in European and Asian studies. The study results were published in the scientific journal Prostate Cancer and Prostatic Diseases in early 2026.

Veterans Affairs is one of the world's largest integrated health care systems, covering about six percent of insured residents with health insurance in the U.S. Cedars-Sinai ranks among the top ten most influential hospitals in the U.S.

Additionally, the study results show that there is no statistical difference in the performance of Prostatype® between African-Americans and Caucasians, which is of great importance not least for the American market.

Additional regional studies

More regional studies with Prostatype® have been conducted with consistently positive results, including a pilot study in China with 100 patients.

Selected progress in 2025

Market approval and commercial progress in the U.S.

- During the year, the company continued to work on the ongoing Medicare application for Prostatype® cost reimbursement in the U.S. All supplementary questions received have been answered. Obtaining Medicare approval is fundamental for the company's continued commercial activities in the U.S., as Medicare treats approximately 60 percent of the country's prostate cancer patients.
- During the spring, it was announced that clinical use of Prostatype® had started at several of the 10 highest-ranked U.S. hospitals/urology clinics within prostate cancer. The company thus achieved its goal regarding clinical and scientific weight among the reputable urologists who use Prostatype® in the initial launch phase.
- In June, the company engaged Healthcare Capital Mergers, LLC, Chicago as transaction advisor to identify one or more strategic investors and/or commercial partners, primarily in the United States. The collaboration is in line with the previously communicated business plan to initially launch Prostatype® in the U.S. under the company's own management, followed by scaling up with one or more major partners.
- In August, an important commercial milestone was reached when the company began invoicing several insurance companies in the U.S. for the use of Prostatype®. This progress meant that the company started generating sales revenue in the U.S., albeit initially on a small scale, in the second half of 2025.
- In November, it was announced that the company's ongoing research and development work has made it possible to identify several new applications and products based on the technology already developed by the company. The first new product, for prognostic decision support after radical treatment of prostate cancer, has already been clinically validated in collaboration with Uppsala University Hospital, with expected scientific publication in the first half of 2026.

Commercial progress in Europe

- During the first half of the year, deliveries were initiated within the framework of the order worth approximately 1.8 MSEK to the University Hospital Policlinico Tor Vergata in Rome, Italy, which was presented at the end of 2024. This also meant that clinical use in Italy was initiated.

Strengthened scientific support for the Prostatype® genetic test

- In February, it was announced that the results of a health economic study with Prostatype® had been published in the scientific journal PharmacoEconomics. The results show that Prostatype® can contribute with just over 800 MSEK in annual health economic benefit in Sweden alone compared to the methodology for risk classification of diagnosed prostate cancer that is used in the Swedish healthcare system today.
- In March, positive preliminary results from the U.S. study led by Professor Stephen Freedland of the Department of Urology at Cedars-Sinai, and in collaboration with the Durham Veterans Affairs Healthcare System. The preliminary results, which were confirmed in the beginning of 2026, show that Prostatype® has a strong prognostic potential in identifying patients at high risk of disease progression, and that it is equally effective in predicting mortality from prostate cancer.
- In June, strong results from a study in Taiwan with Prostatype® were published in a scientific journal. Prostatype® showed superiority in predicting prostate cancer-specific mortality compared to the guidelines of the National Comprehensive Cancer Network (NCCN®), as well as compared to PSA and magnetic resonance imaging (MRI).
- In July, positive results from a Spanish multicentre study with Prostatype® were published in a scientific journal. The study included 93 patients with prostate cancer at seven hospitals, and Prostatype® delivered significantly better prognostic performance than the NCCN®, D'Amico and EAU benchmarks for both the risk of prostate cancer-specific mortality within 10 years and the risk of metastasis.

Progress so far in 2026

Publication of results from U.S. validation study

- In January, the clinical evidence was further strengthened with the publication of the company's U.S. validation study for Prostatype® in the medical journal Prostate Cancer and Prostatic Diseases. The study, conducted in collaboration with Veteran Affairs and Cedars-Sinai Health System, included a diverse patient population and showed once again that the test demonstrates strong and significant prognostic ability to support clinical decisions in prostate cancer diagnostics. This publication further strengthens the evidence base in the U.S. and contributes to increased clinical credibility in the most important international market.

Objectives in 2026-2027

2026

- Results from a long-term study with Prostatype® in collaboration with Uppsala University Hospital
- Medicare approval for reimbursement in the U.S. (current reimbursement approx. 3,700 USD per test)
- Focused sales activities towards selected states and urology groups (LUGPA groups)
- Increasing reimbursement based sales revenue in the U.S.
- More commercial agreements in selected EMEA markets (Europe and Asia)

2027

- Up-scaling of U.S. sales with significant recurring revenue
- Rising revenues from selected EMEA markets (Europe and Asia)

Interview with Håkan Englund, investor and board member at Prostatype Genomics

Håkan Englund, life science investor and board member at Prostatype Genomics, brings a lot of knowledge and experience to the Company, both as a long-term investor as well as having spent his professional career in the life science industry. In this interview Håkan shares his view on Prostatype Genomics and why investing in the Company is an exciting opportunity.

Håkan – can you introduce yourself and your background both professionally as well as an investor in various life science companies?
I am currently acting as CEO and owner of JDS Invest focusing on investing in interesting companies within the life science industry, where Prostatype Genomics is one of several portfolio companies. I have worked more than 30 years in the life science industry, based both in Sweden as well as in North America where I held several leading management positions at both Pharmacia Biotech and Phadia. As I have a background from, and a broad network within, the life science community, I try to bring my experiences into the companies I invest in, both as a long-term investor as well as from a professional point of view.

With this experience, why have you chosen to invest and take an active role in Prostatype Genomics as board member?
I started to invest in Prostatype Genomics already back in 2014, so I have been involved in the company quite a while now, seeing it grow and mature over the years. I understood early that genetic testing and precision medicine brings a fantastic opportunity to the health care systems, payers but especially to the patients. Cancer has a genetic origin, so to bring the important gene parameter into the mix to be able to more accurately prognose the progression for individual patients is important. This is especially true taking the specific challenges in prostate cancer into consideration. It is a well known challenge that it is difficult to classify a diagnosed prostate cancer patient into the correct risk group which unfortunately leads to a situation where many patients get overtreated. The consequences are that overtreatment brings unnecessary costs to the health care system, but also lifelong side effects for the patients like impotence and incontinence, negatively influencing the patients' quality of life. Precision medicine is all about being able to provide the right treatment to the right patient at the right time – that is exactly the kind of information Prostatype® brings.

The fact that Prostatype Genomics is focusing on prostate cancer, the most common form of cancer among men in North America and Europe, makes the company even more interesting also from a commercial and financial point of view. To be able to support patients as well as the health care systems to take more individualized and precise decisions patient by patient is important.

Looking at Prostatype Genomics and achieved milestones the past couple of years, what is your take on that?
Prostatype Genomics is a very interesting company, present in a large and growing market. Looking at the development over the past couple of years, we have chosen to focus our efforts and resources towards the US market. We also have a footprint in Europe and making progress also on this side of the Atlantic, but the market infrastructure in USA is completely different compared to Europe. In USA prognostic biomarkers like Prostatype® is already reimbursed at an attractive level as well as being included in clinical guidelines. In Europe none of these fundamental parts of the infrastructure are in place, making it quite challenging for a small company like Prostatype Genomics to commercially break through without heavy investments. We understood this challenge early in the launch process which made it quite an easy decision to focus our resources on where we will get the best return on our investments, which is USA.

As Prostatype Genomics already have invested in and built up the American infrastructure, what would you say are the most important targets for the Company at this moment?
We are in the final phase with Medicare regarding reimbursement for Prostatype® in USA – that is and has been our main priority for some time now. We had hopes that the approval would come quicker than it has, as the so-called LCD-code already was existing when we submitted our original submission as well as the established reimbursement level. We have a strong team both in Sweden as well

as in USA that are working together with Medicare in this process and we are making constant progress. For many of us it is easy to feel frustration from time to time as the Company has been in this process quite a while now, but regulatory processes are always very difficult to put a time limit on. I have experienced similar situations in other companies and in other countries over the years as well. There are so many parameters playing a part in the process, and the majority of those are not controlled by the company. What the company needs to do, and does, is to constantly provide Medicare with clear and relevant answers to the requested information from time to time. We are step by step getting closer to the approval we all want to see.

Another exciting opportunity for the future is that Prostatype Genomics has worked on expanding the intended use for Prostatype®. The product as we know it today helps the patient and physicians to take a more accurate decision to answer the question if surgery (radical treatment) really is needed or not. Prognostic biomarkers like Prostatype® are actually also used after a patient has undergone surgery, in order to answer the question if additional treatment, for example radiation or hormone treatment, is needed or not. This part of the total market represents approximately 30% of the total market, so it is natural that we want to expand the usage of Prostatype® also into this market segment. We have already completed the first study which will be published later this year, and the preliminary results looks very positive. The addition of the expanded intended use opens up quite a few interesting commercial opportunities including future potential collaborations with larger pharmaceutical companies, mainly those that are present in the hormone treatment segment.

It is interesting to reflect on the investments Prostatype Genomics has done over the past couple of years, both in Europe as well as in USA. As our main focus is USA, we decided early in the process to build the needed infrastructure as quickly as possible, to be fully prepared to launch Prostatype® more broadly as soon as we receive reimbursement from Medicare. We have already invested in all the permits and regulatory licenses that are needed for commercialization in the USA. We also have a very good laboratory partner in place, ResearchDX in California. The fact that Prostatype® already is in clinical use in USA is also an important step that will shorten the time it will take for us to grow sales once we receive the Medicare reimbursement approval.

Once Prostatype Genomcis receives the reimbursement approval, what will be the focus points then?
When it comes to Prostatype®, our main point is to show commercial scalability as quickly and efficiently as possible. In other words that we see a rapid and stable increase in sales volumes. We have chosen to launch Prostatype® on our own and not engage with a commercial partner initially. We have been through a number of scenarios before reaching this decision, but we are also aware that we sooner or later will engage in a partnership with an American company, in order of fully unlock the commercial potential of Prostatype®. The profile of a future partner does however need to fit the specific sales and marketing needs unique to prognostic biomarkers. In our case this means that we most probably will not enter into a partnership with a laboratory chain, but rather with an organization that has existing relationships with urologists as the clinicians are the real customers for products like Prostatype®.

Having been deeply involved in product launches in USA in the past, I can also add that any success will come from close monitoring of KPI:s (Key Performance Indicators) in order to understand how the market reacts and what potential adjustments that are needed in order to optimize the commercial activities.

Where do you see the company in 2-3 years from now?
Having worked with numerous mergers and acquisitions throughout my career, I have learned that companies that successfully combine strong clinical evidence, clear commercial relevance and an established presence in the U.S. market often develop strongly as they reach key milestones. At the same time, the field of molecular oncology diagnostics continues to be characterized by industry consolidation, particularly in the U.S., where many of the sector's leading players are based and where a significant share of industry transactions have taken place in recent years. Looking ahead two to three years, I envision Prostatype Genomics having further strengthened its position in the U.S. market, expanded the use of its technology and taken important steps towards realizing the Company's long-term potential.

Thank you, Håkan – it has been interesting to talk to you. Finally, as one of the larger shareholders of Prostatype Genomics, how do you view the Company as an investment opportunity?
As I mentioned earlier, I have been investing in Prostatype Genomics for more than 10 years now. We have made all the costly investments from a product development point of view where Prostatype® already is commercially and regulatory approved and launched both in Europe as well as in USA. Saying this, we are planning to expand our product portfolio to other areas linked to prostate cancer, where the level of investments will be significantly lower as we are able to extract significant synergies based on the investments already done with Prostatype®. This is true from a commercial, regulatory as well as from an R&D point of view.

A Medicare approval would represent a very important step in the company's commercial plan and, combined with the strengthened evidence base and the company's strategic positioning, I believe that Prostatype Genomics has good prospects for continued development in the coming years.

Key figures

Group

TSEK	2025	2024	2023	2022	2021
Net sales	594	199	1,356	683	10
EBITDA	-36,751	-38,874	-37,372	-26,785	-15,460
Total Assets	50,862	41,970	49,222	30,950	40,203
Total Equity	26,529	33,469	24,674	26,151	35,906
Net cash flow	-330	6,686	-8,793	-8,840	4,467
Equity/Assets-ratio	52%	80%	50%	84%	89%
Average number of employees	7	6	7	6	5
Equity per share, SEK *	0.45	4.99	206.54	1,143.99	2,379.64
Earnings per share, SEK * **					
- Before and after dilution	-1.32	-14.93	-512.68	-1,597.90	-1,120.57
Number of shares at the end of the period	59,189,321	6,704,770	119,460,007	22,859,497	15,088,761
Number of shares at the end of the period after full dilution	59,189,321	6,704,770	119,460,007	30,775,263	19,133,952
Weighted average number of shares for the period	33,783,778	1,410,722,766	80,819,803	18,202,992	13,947,626

* Values for historic earnings and equity per share have been recalculated to reflect the reversed share split 1000:1 decided upon at the extraordinary general meeting on 22 October 2024.

** The definition of earnings per share has been updated to be calculated on the average number of shares for the period instead of on the number of shares at the end of the period. All comparative figures have therefore been adjusted.

Definitions of key ratios

Profit margin	Year's profit/loss / net sales
Equity ratio	Adjusted equity / total assets
Earnings per share	Net profit/loss for the year / average number of shares for the period
Diluted earnings per share	Net profit/loss for the year / average number of shares + warrants for the period

Directors' report

The Board of Directors and the CEO of Prostatype Genomics AB, 556726-0285, with its registered office in Stockholm, hereby submit the annual report for the financial year 2025-01-01 – 2025-12-31.

General information about the business

Prostatype Genomics' business concept is to develop and commercialize prognostic methods against cancer. The first project concerns Prostatype®, a product for the classification of prostate cancer, which is the most common cancer among men in many countries, in particular in Western Europe and North America.

About 10,000 men in Sweden and 500,000 in Europe are diagnosed with prostate cancer annually. In the US 300,000 per year. Most people, about 65 percent, have a slowly growing cancer and the risk is small that the disease will become really serious in ten to fifteen years' time. Methods used today for diagnosis and prognosis are serum PSA, assessment of tissue samples from the prostate according to the Gleason Score and other clinical assessments. These methods are not sufficient to be able to assess the future development of the tumour in the early stages of the disease in the individual patient. Since the prognosis methods used today are uncertain, men with slowly growing cancer risk being unnecessarily treated with radical methods such as prostatectomy and/or radiotherapy, which often leads to side effects such as urine leakage, impotence and gastrointestinal problems, which in turn leads to reduced quality of life for the individual patient.

A method that can determine a tumor's development in direct relation to treatment choices provides the opportunities to individualize treatment according to the patient's needs. A classification of patients' prognosis also lowers healthcare costs by limiting resource-intensive treatments to patients whose tumour disease has a more negative prognosis.

The company has granted patents for Prostatype® in Europe, Japan, Hong Kong, Canada, China and in the U.S.

Group relationship

The group consists of the parent company Prostatype Genomics AB (reg. no. 556726-0285) and the wholly owned subsidiary Prostatype Genomics Inc., (reg. no. 6005878), Delaware, USA.

Significant events during the financial year

Commercial progress in the U.S.

Ongoing Medicare reimbursement application for Prostatype® in the U.S.
In the beginning of 2025, Prostatype Genomics announced that supplementary questions had been received from Medicare following the review of the application, and the company submitted answers in early February. Thereafter, the dialogue with Medicare continued during the year within the framework of the processing of the company's application (within the framework of the MolDX program). Obtaining Medicare approval is a key prerequisite for the company's continued commercial efforts in the U.S., as Medicare treats around 60 percent of all patients with prostate cancer, and the agency is also influential for other insurers and paying parties in the country.

Leading American urologists have started using Prostatype® clinically
On May 15, 2025, it was announced that the number of selected American urologists at well-respected urology clinics/hospitals who use Prostatype® clinically is gradually increasing and now exceeds 10 in total. The company has thus achieved its goal in terms of clinical and scientific weight among the reputable urologists who use Prostatype® in the initial launch phase. A major focus is now on ensuring an efficient and scalable integration of the test into the work routines of all of these clinics/hospitals.

In a newsletter published in June 2025, it was clarified that Prostatype® has now begun to be used clinically at several of the U.S.'s 10 highest-ranked hospital/urology clinics in prostate cancer according to publicly available ranking lists.

American billing partner engaged to handle reimbursement
On May 15, 2025, it was also announced that a billing partner with many years of experience has been engaged to handle cost reimbursement from both Medicare and other federal and private health insurers in the United States. The company is thus actively working to start receiving reimbursement also outside of Medicare.

Initiated invoicing for Prostatype® to insurance companies in the U.S.
On August 26, 2025, it was announced that Prostatype Genomics had reached an important commercial milestone in the U.S. by starting to invoice several insurance companies for Prostatype®. As the U.S. patient insurance market consists of hundreds of insurers of various sizes, Prostatype Genomics' revenues in the U.S. will not come from just one individual insurer. This progress meant that the company started generating sales revenue in the U.S., albeit initially on a small scale, in the second half of 2025.

Preparations ahead of strategic partnerships/ investments in the U.S.

The company's share available for trading in the U.S. via OTCQB Venture Markets
On March 13, it was announced that the company's share has been made available for trading in the United States via the OTCQB Venture Market in parallel with the current listing on Nasdaq First North in Stockholm. The stock is thus available to U.S. brokers and investors during U.S. trading hours, with the U.S. ticker OTCQB: PGABF and pricing in in USD. For avoidance of doubt, the share is not listed in the U.S., it can be traded in the U.S through the QTCQB service.

Healthcare Capital Mergers engaged as U.S. transaction advisor
On June 2, the company announced that Healthcare Capital Mergers, LLC, Chicago has been engaged as transaction advisor to identify one or more strategic investors and/or commercial partners, primarily in the United States. The collaboration is in line with the previously communicated business plan to initially launch Prostatype® in the U.S. under the company's own management, followed by scaling up with one or more major partners.

Completed R&D investments enable the development of new products in addition to Prostatype®
On November 11, it was announced that the company's ongoing research and development work has made it possible to identify several new applications and products based on the technology already developed by the company. The first new product has already been clinically validated in collaboration with Uppsala University Hospital, with expected scientific publication in the first half of 2026.

The company's current product Prostatype® is used as a prognostic tool for risk assessment of patients' prostate cancer before decisions are made on radical treatment (surgery, radiation or hormone therapy). The new product also offers prognostic risk assessment after completion of radical treatment.

Commercial progress in Europe

Initiated delivery and clinical use of Prostatype® in Italy
During the first half of the year, deliveries were initiated within the framework of the order worth approximately 1.8 MSEK to the University Hospital Policlinico Tor Vergata in Rome, Italy, which was presented at the end of 2024. This also meant that clinical use in Italy was initiated. Prostatype Genomics is also working to sign agreements with additional similar clinics in other parts of Italy.

Strengthened scientific support for the Prostatype® genomic test

Prostatype® can contribute with 800 MSEK per year in health economic benefit in Sweden
On February 10, it was announced that the results of a health economic study with Prostatype® had been published in the recognized scientific journal PharmacoEconomics. The study and a complementary analysis, both conducted by the Institute for Health Care Economics (IHE), show that Prostatype® can contribute with just over 800 MSEK in annual health economic benefit in Sweden alone compared to the methodology for risk classification of diagnosed prostate cancer that is used in the Swedish healthcare system today.

Positive preliminary results from the U.S. study with Prostatype®
On March 31, positive preliminary results from the U.S. study led by Professor Stephen Freedland of the Department of Urology at Cedars-Sinai, and in collaboration with the Durham Veterans Affairs Healthcare System. The preliminary results indicate that Prostatype® has a strong prognostic potential in identifying patients at high risk of disease progression, and that it is equally effective in predicting mortality from prostate cancer. Notably, no significant difference was observed in the performance of the test between African-American and Caucasian patients.

Strong results for Prostatype® in published Taiwan study
On June 3, the company announced that strong results from a study in Taiwan with Prostatype® had been published in the scientific journal BJUI Compass. In the study, Prostatype® showed superiority in predicting prostate cancer-specific mortality compared to the guidelines of the National Comprehensive Cancer Network (NCCN®), as well as compared to PSA and magnetic resonance imaging (MRI). Clinical validation of Prostatype® is ongoing at a leading hospital in Taiwan, and this publication also opens up for expansion to other major Asian markets with suitable partners.

Positive results for Prostatype® in published Spanish multicentre study
On July 22, it was announced that previously communicated positive results from a Spanish multicentre study with Prostatype® had been published in a peer-reviewed scientific article. The study included 93 patients with prostate cancer at seven hospitals, and Prostatype® delivered significantly better prognostic performance than the NCCN®, D'Amico and EAU benchmarks for both the risk of prostate cancer-specific mortality within 10 years and the risk of metastasis. The practical benefit of the test was clearly demonstrated as the treatment plan could have been modified for as many as 39% of the patients in the study if Prostatype® had been used as a decision basis at the time of confirmed diagnosis. The multicentre study was coordinated by the Spanish National Urology Association, and the results were presented at their annual meeting in April 2024.

Financing of the company's operations

Fully subscribed rights issue of approximately 27.3 MSEK
On June 5, it was announced that the rights issue of units carried out during May-June had been fully subscribed, which meant that the company received approximately 27.3 MSEK before transaction-related costs and repayment of bridge loans. On June 18, it was announced that a directed share issue had been carried out to the guarantors in the rights issue, as all requested compensation in units instead of cash. Following the registration of the rights issue and the directed issue to the guarantors, the total number of shares in the company amounts to 37,000,265 and the share capital to 3,700,026.50 SEK. In connection with this, 22,623,789 warrants of series TO 5 were issued.

The company receives 11.5 MSEK from redemption of TO5 warrants
On September 18, it was announced that the company's warrants of series TO5 were exercised, including activated top-down guarantee commitments, to approx. 98.1 percent. This meant that the company received approx. 11.5 MSEK before deduction of transaction-related costs.

Multi-year overview

	Group				Parent company
TSEK	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Net sales	594	199	1,356	683	10
Earnings before depreciation (EBITDA)	-36,751	-38,874	-37,372	-26,785	-15,460
Balance Sheet	50,862	41,970	49,222	30,950	40,203
Equity	26,529	33,469	24,674	26,151	35,906
Cash flow	-330	6,686	-8,793	-8,840	4,467
Solidity	52%	80%	50%	84%	89%
Earnings per share*	-1.32	-14.93	-512.68	-1,597.90	-1,120.57

* Values for historic earnings and equity per share have been recalculated to reflect the reversed share split 1000:1 decided upon at the extraordinary general meeting on 22 October 2024.

Earnings and financial position

Turnover and results

Net sales amounted to 594 TSEK (199), of which 112 TSEK (0) is related to the United States. The company is still in the initial phase of commercialization, and thus the net sales is in line with expectations.

Operation profit/loss for the company (EBIT) and operating profit before depreciation and amortization (EBITDA) amounted to -38,938 TSEK (-40,853) and -36,751 TSEK (-38,874), respectively. The company's costs mainly consist of research, testing, personnel and commercialization.

Earnings per share for the period amounted to -1.32 SEK (-14.93), where recalculation was made to reflect the 1000:1 reverse share split that was carried out during the second half of 2024.

Investments

Investments relate primarily to product development in and towards the United States and a total amount of 13,359 TSEK (8,356) has been balanced.

The group's intangible assets represent values for expenses, development work and patents regarding the company's product. Development expenses and patents are written of on a straight-line basis over 10 years.

Cash flow and cash and cash equivalents

Net cash flow during the period amounted to -330 TSEK (-6,686). The Group's cash and cash equivalents at the end of the period amounted to 9,068 TSEK (9,420).

During the year, the company has received capital via a rights issue and warrants of series TO5 totalling 41.7 MSEK before issue costs.

Personnel

At the end of 2025, the group had 7 (7) employees, of which 2 (2) were women.

The parent company

The parent company's income and operating result for the period amounted to 482 TSEK (199) and -25,319 TSEK (-30,293), respectively. The company invested 13,182 TSEK (3,816) in product development and financed subsidiaries with 9,507 TSEK (11,455). Net cash flow amounted to -835 TSEK (7,233) and cash and cash equivalents at the end of the period amounted to 8,467 TSEK (9,302).

Significant events after the end of the financial year

Publication of U.S. validation study

The clinical evidence was further strengthened with the publication of the company's U.S. validation study for Prostatype® in the medical journal Prostate Cancer and Prostatic Diseases. The study, conducted in collaboration with Veteran Affairs and Cedars-Sinai Health System, included a diverse patient population and demonstrated once again that the test demonstrates strong and significant prognostic ability to support clinical decisions in prostate cancer diagnostics. This publication further strengthens the evidence base in the United States and contributes to increased clinical credibility in the most important international market.

Loan financing

In December 2025 and January 2026, the company was provided with additional financial flexibility through the signing of short-term loans totalling 10 MSEK, including loans from both major shareholders and external lenders. The financing aims to secure short-term working capital without an immediate dilution effect for the shareholders.

Proposal for resolution on rights issue

On May 19, 2026, the company announced the board's intention to resolve on a rights issue of units (shares and two series of warrants) of approximately SEK 47.4 million before issue costs. The rights issue is secured to approximately 70 percent through subscription commitments and guarantee commitments and is intended to finance the continued

Medicare process and commercialization activities in the US and Europe. Warrants of series TO6 and TO7, if fully exercised, may provide the company with additional capital of a total of approximately SEK 60 million before issue costs.

Liquidity, financing, capital requirements

The board of directors makes the assessment that the group is dependent on additional capital injections until a positive operating cash flow is reached.

Based on ongoing financing activities, it is the board's assessment that the group will secure the liquidity required for the needs of the business. The board of directors works proactively to secure growth capital through a combination of debt financing, new issues and strategic collaborations to accelerate commercialization. It is the Board's overall conclusion that these measures will ensure continued operations, which is why the report is prepared with the going concern assumption.

However, the board of directors would like to draw attention to the fact that if the necessary additional financing is not realised, this will constitute a material uncertainty factor for the group's ability to continue operations over the next 12 months.

The share

The company's share is listed on the NASDAQ First North Growth Market under the symbol PROGEN, and it is traded with ISIN code SE0023261532.

On 31 December 2025, the share capital amounted to 5,918,932 SEK (670,477) distributed over 59,189,321 shares (6,704,770). The increase in due to the rights issue of units that included warrants of series TO5, which were issued and subscribed for in 2025. All shares are issued and fully paid.

Since March 13, 2025, the company's share is also available for trading on the OTCQB Venture Market in the U.S., which means that the share there can be traded in parallel with its listing on Nasdaq First North in Stockholm, during U.S. trading hours, with a U.S. ticker (OTCQB: PGABF) and pricing in USD. pricing in USD. For avoidance of doubt, the share is not listed in the U.S., it can be traded in the U.S through the QTCQB service.

Largest shareholders

The largest individual shareholders in Prostatype Genomics AB at the end of the financial year are Hans Öhman (17,7%), Filip Norlin (10,7%), Gerald Andriole (6,2%) and Håkan Englund (4,1%).

A list of the largest shareholders can be found on the company's website (www.prostatypegenomics.com).

Transactions with related parties

Shareholder loans

In December 2025 and January 2026, the company signed short-term loan agreements with board members and major shareholders, of which 2.0 MSEK with board members, Håkan Englund with 1.5 MSEK, Anders Lundberg with 0.2 MSEK, Michael Häggman with 0.2 MSEK and Jörgen Dahlström with 0.1 MSEK. The loans have a fixed period interest rate of 15% and run until June 30, 2026. The loans were signed privately or through controlled companies and the loan terms are deemed to be at market terms.

Consultancy fees

Board member Mattias Prage is employed at Advokatbyrån Lindahl KB, which the company engages for advice on legal issues and company administration. During the year, Lindahl invoiced the company 645 TSEK (1 036).

Board member Jörgen Dahlström is CEO of Mercodia AB, which has purchased consulting services from the company for 145 TSEK (0).

Johan Waldhe, who was a board member up until the 2025 annual general meeting, is CEO of the communications and consulting company Honeybadger AB. Services for 616 TSEK (711) were procured during the time of the board assignment.

Financial and operational risks

Through its operations, the group is exposed to both financial and operational risks. The financial risks mainly consist of liquidity and financing risks, while the operational risks include, among other things, market-related, regulatory and commercial risks linked to the company's development and commercialization.

Financial risks

Financing and continued operation

The Company is in an establishment phase where expected cash flows from the Company's operating activities do not cover planned costs and investments in the form of launching in new markets. The company's assessment is that current financing is not sufficient to continue operations to the extent planned for the next twelve months and there is a risk that the company will not be able to raise additional capital or that such financing cannot be obtained on, for existing shareholders, favorable terms. There is also a risk that such financing will not be obtained to a sufficient extent or that it will be delayed, which may lead to the commercialisation of Prostatype® being slowed down or not being achieved at all. In such a scenario, the Company may be forced to conduct operations at a slower pace than planned, which could lead to delayed or lost revenues and negatively affect the Company's establishment in the United States, which could have a negative impact on the Company's operations, financial position and earnings. Prostatype Genomics assesses the probability of risk occurring as medium.

The Company further assesses that the risk, if realized, would have a high effect on the Company, its financial position and continued operations.

Valuation of assets

The company's product, Prostatype®, is in a commercialization phase. In addition to the short-term financial risk

mentioned above, there is, as for all businesses, a long-term risk that objectives will not be achieved within the time frame on which the group's forecasts are based.

The Group's balance sheet contains significant intangible assets, mainly attributable to capitalized development costs. The value of these assets is dependent on the company's ability to successfully commercialize its products and generate future cash flows.

If the sales do not reach set goals or if the assumed cash flows are not realized at the rate assumed by the board and company management or are alternatively postponed in time, this may affect the valuation of the Group's assets. Changes in the assumptions on which the impairment test was based may result in the assets needing to be written down at a faster pace than planned, which may affect earnings and the financial position.

Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if realized, would have a high effect on the Company.

Operational risks

Market acceptance

The company's product, Prostatype®, is in a commercialization phase. At the date of this report, Prostatype® has been made available to sell in Sweden, Spain, the UK, Norway, Italy and the U.S. However, there is a risk that the sale does not fully meet the Company's objectives and that the product will not be commercially successful. The level of market acceptance and sales of Prostatype® depends largely on whether the product succeeds in gaining recognition among urologists, but also on a number of other factors, such as product characteristics, clinical documentation and results, competing products, distribution channels, availability, price, compensation, sales and marketing efforts and that the product is mentioned and noticed in various trade journals. If the Company and its product do not receive sufficient visibility in the relevant channels, it may cause delays in the market acceptance or a total or partial failure of such market acceptance to occur.

Since Prostatype® has not yet generated any significant revenue, it is difficult to evaluate the sales potential of the product. The product is a support in healthcare choices for the treatment of prostate cancer and aims to avoid unnecessary operations. The company intends to initially conduct sales to private healthcare (private hospitals, insurance companies and out-of-pocket patients). To achieve the market penetration required to achieve the Company's financial targets, a small number of urologists in the target group need to be convinced. The company considers this as realistic, but there is a risk that the introduction will take longer than expected. In public healthcare, it takes longer to reach acceptance, and the Company will be dependent on the national reimbursement systems. The risk is therefore considered to be low in relation to private healthcare and medium in public healthcare. A certain conflict of interest can be considered to exist between private healthcare providers' willingness to perform surgeries and the Company's ambition to avoid unnecessary ones, which risks affecting market acceptance.

Medical technology is generally a market area characterized by global competition, rapid technological development, regulatory requirements, and extensive investment requirements. Prostatype Genomics estimates that there is currently no product on the European market that fully corresponds to Prostatype®, but that there are companies in medical technology that may become potential competitors to Prostatype Genomics, e.g., by these companies developing an equivalent product. Should competitors develop products that prove to be better than the Company's, it could have a material adverse effect on the Company's business, sales, market acceptance, financial position and results of operations as other Companies may take market shares.

The competitive situation in the US market is different as there are a few US companies that manufacture products comparable to Prostatype®. In the US market, the Company may thus be exposed to competition from existing competitors who want to prevent or complicate the marketing of Prostatype® in various ways, e.g., by challenging the Company's patents.

Overall, Prostatype Genomics estimates that the probability of the risk occurring is medium.

Dependence on key personnel

Prostatype Genomics is a small organization with limited resources. The Company's success is largely dependent on a qualified workforce and on the extensive expertise and long experience in the Company's area of operation that the employees possess. In light of the organization's size and competence profile, each employee is considered an important resource for the business. One of the Company's main strengths is the internal knowledge of advanced laboratory technology, AI technology and data analysis, which is partly linked to the Company's personnel. If several key employees were to leave within a short period of time, it would have a significant negative effect on the Company's ability to conduct the business and achieve the results the Company seeks. It could also delay the Company's operations and negatively affect its ability to achieve commercial goals.

Prostatype Genomics assesses the probability of occurrence of the risk as low. The Company further assesses that the risk, if realized, would have a high effect on the Company.

Regulatory risks associated with studies and permits

Before medical devices, such as Prostatype, can be launched on the market, their performance and safety must be ensured, which Prostatype® Genomics has done through clinical studies as well as validation studies in several countries. Prostatype Genomics' strategy is to conduct validation studies in each country where sales are intended to be conducted, which does not follow from regulatory requirements but rather from practice. In order to be able to market and sell medical devices, in some cases a permit must also be obtained, and registration must take place with the relevant authority. Prostatype® is CE-marked and approved according to IVDR and the Company has at the date of the publication of this annual report permission to sell the product in Europe. The company has conducted a

validation study in China and has an ongoing validation study in Taiwan and the U.S. In the U.S., the Company has no ambition to secure FDA approval, and has instead launched Prostatype® as an LTD approved product and so-called CLIA accreditation, which shortens the time to market launch and reduces financial risk. Competing products in the U.S. are also offered as LDT products.

There is a risk that ongoing and planned validation studies will be delayed or not yield expected results, which may affect the Company's ability to commercialize its products in new markets and thereby affect revenue development.

The studies conducted by Prostatype Genomics are associated with uncertainty and risk regarding delays and results. There is a risk that results in the Company's ongoing and future studies will not be satisfactory and there is a risk that the Company's future products for safety and/or efficiency reasons will not be demonstrated to be as good as previously estimated. Furthermore, there is a risk that the rules and interpretations that currently apply regarding registration and permits for the Company's product may change in the future, which in that case could affect the Company's ability to meet the requirements of various authorities. Thus, changes in rules and interpretations as well as revoked permits and registrations may also cause delays in market launches in certain markets and risk reducing the Company's growth rate and expected profitability. All in all, it could have a negative impact on the Company's business, financial position and results.

Prostatype Genomics assesses the probability of occurrence of the risk as low. The Company further assesses that the risk, if realized, would have a medium effect on the Company.

Intellectual property rights and patent protection
Prostatype Genomics depend on the ability to obtain and defend patents, other intellectual property rights and reprocessed know-how. Patent protection for medical device companies can be uncertain and cover complex legal and technical issues. Prostatype Genomics has applied for and been granted patents until 2032 in the US, Canada, China, Hong Kong, Japan and Europe (EPO). In the event that future patent applications are not granted, it could adversely affect Prostatype Genomics' operations and financial position. Furthermore, patents usually have to be applied for and maintained in several different jurisdictions and generally have a limited lifespan. There is a risk that the existing and/or future patent portfolio and other intellectual property rights held by the Company will not constitute adequate commercial protection, or that the Company will or is alleged to infringe the intellectual property rights of third parties. If Prostatype Genomics is forced to defend its patent rights against a competitor, this may entail significant costs, which may adversely affect Prostatype Genomics' business, results and financial position. Furthermore, there is always a risk in the type of business that Prostatype Genomics conducts that the Company may make or is alleged to infringe patents held by third parties.

To date, the Company has not been involved in any dispute regarding patents. The uncertainty associated with patent protection means that the outcome of such disputes is difficult to predict, but it could lead to costly litigation and negative publicity. The effect could be delays or obstacles to continued commercialization of the product and thus also difficulties for the Company to generate revenue.

Prostatype Genomics is also to some extent dependent on know-how and trade secrets, which are not protected by law in the same way as intellectual property rights. The company uses confidentiality agreements and thereby strives for far-reaching protection of sensitive information. However, it is not possible to fully protect yourself against unauthorized dissemination of information, which entails a risk that competitors will get access to and benefit from the know-how developed by Prostatype Genomics, which could be detrimental to the Company.

Overall, Prostatype Genomics assesses the probability of the risk occurring as low. The Company further assesses that the risk, if realized, would have a high effect on the Company.

Forward-looking statements

Certain statements in this report are forward-looking and actual results may difer materially. In addition to the factors discussed, other factors may have an impact on actual outcomes. Such factors include developments for customers, competitors, efects of economic and market conditions, national and international laws and regulations, tax regulations, fuctuations in exchange rates and interest rates and political risks.

Proposed appropriation of retained earnings

Retained earnings (SEK) in the parent company at the disposal of the annual general meeting:

Share premium reserve	211,816,929
Retained earnings	-154,346,577
Profit/loss for the year	-34,646,520
	22,823,832

The board of directors proposes that the retained earnings are to be appropriated as follows:

Carried forward	22,823,832

The group's and parent company's profit/loss as well as the company's financial position in general are disclosed in the following income statements, balance sheets, cash flow statements and additional information.

The income statement and balance sheet will be adopted at the AGM on June 10, 2026.

Income statement

		Group		Parent company	
TSEK	**Note**	**2025**	**2024**	**2025**	**2024**
Net sales	3	594	199	482	199
Own work capitalized	7	-	1,719	-	-
Other operating income		3	65	3	65
Total income		**597**	**1,983**	**485**	**264**
Operating expenses					
Research and development cost		-1,464	-2,211	-1,464	-2,211
Other external costs	5	-20,798	-22,355	-14,323	-17,099
Staff cost	5	-15,225	-15,709	-8,068	-8,675
Depreciation, amortization and impairment	7,8,9,10,11	-2,187	-1,979	-2,089	-1,899
Other operating expenses		139	-583	139	-410
Operating profit/loss		**-39,535**	**-42,836**	**-25,804**	**-30,293**
Operating profit/loss		**-38,938**	**-40,853**	**-25,319**	**-30,029**
Interest income and similar items		90	43	2,454	1,507
Interest expense and similar items	18	-1,615	-1,677	-1,615	-1,677
Other financial items		-	-	-6,126	-12,285
Currency effects	18	-4,041	1,436	-4,041	1,434
Profit/loss after financial items		**-44,503**	**-41,051**	**-34,647**	**-41,051**
Taxes	6	-	-	-	-
Net profit/loss for the period		**-44,503**	**-41,051**	**-34,647**	**-41,051**

Balance sheet

		Group		Parent company	
TSEK	**Note**	**2025-12-31**	**2024-12-31**	**2025-12-31**	**2024-12-31**
ASSETS					
Capitalized development expenditure	7	37,159	26,591	33,288	21,963
Patents	8	0	0	0	0
Licenses	9	2,125	2,677	446	560
Total non-current intangible assets		**39,285**	**29,267**	**33,734**	**22,522**
Technical equipment	10	247	247	247	247
Equipment and tools	11	205	65	205	65
Total non-current tangible assets		**452**	**312**	**452**	**312**
Investments in subsidiaries	12	-	-	0	0
Loans to subsidiaries	13	-	-	8,963	9,623
Other financial assets		485	566	485	566
Total non-current financial assets		**485**	**566**	**9,448**	**10,189**
Total non-current assets		**40,221**	**30,145**	**43,633**	**33,024**
Finished products		78	95	78	95
Inventory		**78**	**95**	**78**	**95**
Accounts receivable		117	43	117	43
Other receivables		510	1,068	2,448	3,437
Subscribed But Not Paid-Up Rights Issue		-	525	-	525
Prepaid expenses and accrued income		868	674	4,680	2,701
Current receivables		**1,495**	**2,310**	**7,244**	**6,706**
Cash and bank		9,068	9,420	8,467	9,302
Total current assets		**10,641**	**11,825**	**15,789**	**16,102**
TOTAL ASSETS		**50,862**	**41,970**	**59,423**	**49,126**

Balance sheet, cont.

		Group		Parent company	
TSEK	**Note**	**2025-12-31**	**2024-12-31**	**2025-12-31**	**2024-12-31**
EQUITY AND LIABILITIES					
Share capital	14	5,919	670	5,919	670
Other restricted capital		-	-	-	13
Development fund		-	-	11,140	12,996
Total restrictred equity		**-**	**-**	**17,059**	**13,680**
Other capital/premium reserves		211,817	183,687	211,817	183,674
Other equity including net profit/loss for the year		-191,206	-150,888	-	-
Profit/loss brought forward		-	-	-154,347	-115,153
Net profit/loss for the period		-	-	-34,647	-41,051
Total non-restricted equity		**-**	**-**	**22,824**	**27,470**
Total equity		**26,529**	**33,469**	**39,883**	**41,150**
Borrowings	15	-	-	-	-
Total long-term liabilities		**-**	**-**	**-**	**-**
Borrowings, short-term	15	5,300	67	5,300	67
Accounts payable		2,735	2,523	1,151	2,070
Tax liabilities		13	52	13	52
Other current liabilities	16	11,462	2,646	10,890	2,646
Accrued expenses and deferred income	17	4,823	3,213	2,186	3,141
Total current liabilities		**24,333**	**8,501**	**19,540**	**7,975**
Total liabilities		**24,333**	**8,501**	**19,540**	**7,975**
TOTAL EQUITY AND LIABILITES		**50,862**	**41,970**	**59,423**	**49,126**
Pledged securities	19	-	3,614	-	3,614
Contingent liabilities		-	-	-	-

Cash flow analysis

		Group		Parent company	
TSEK	**Note**	**2025**	**2024**	**2025**	**2024**
Profit/loss after financial items		-44,503	-41,051	-34,647	-41,051
Adjustments for items not included in cash flow	18	7,719	916	10,979	11,817
Cash flow from operationg activities before changes in working capital		**-36,785**	**-40,135**	**-23,668**	**-29,234**
Change in inventory		16	109	16	109
Change in operating receivables		264	-244	809	-2,613
Change in operating liabilities		12,703	-4,439	8,042	-4,732
Cash flow from changes in working capital		**12,983**	**-4,574**	**8,867**	**-7,236**
Cash flow from current operations		**-23,801**	**-44,709**	**-14,801**	**-36,470**
Acquisition of intangibles		-13,182	-7,578	-13,182	-3,816
Acquisition of tangibles		-258	-285	-258	-285
Financing of subsidiaries	13	-	-	-9,507	-11,455
Change in financial assets		81	-493	81	-493
Cash flow from investment activities		**-13,359**	**-8,356**	**-22,866**	**-16,048**
Share issue proceeds		31,597	66,151	31,597	66,151
Loans raised		10,550	8,825	10,550	8,825
Loans amortized		-5,317	-15,225	-5,317	-15,225
Cash flow from financing activities		**36,831**	**59,751**	**36,831**	**59,751**
Changes in cash and cash equivalents		**-330**	**6,686**	**-835**	**7,233**
Cash and cash equivalents at the beginning of the period		9,420	2,682	9,302	2,069
Translation differences cash and cash equivalents		-23	52	-	-
Cash and cash equivalents at the end of the period		**9,068**	**9,420**	**8,467**	**9,302**

Equity

The group's change in equity in summary

TSEK	Note #	Share capital	Other capital/ premium reserves	Other equity including net profit/loss for the year	Total Equity
Opening balance 2024-01-01		**7,168**	**177,153**	**-159,647**	**24,674**
Reduction of share capital		-56,942	5,973	50,969	-
New share issues		50,445	11,033	-	61,478
Net share issues, subscribed not paid-up		-	13	-	13
Issue expenses		-	-10,486	-	-10,486
Currency translation differences		-	-	-1,158	-1,158
Profit/loss for the period		-	-	-41,051	-41,051
Closing balance 2024-12-31		**670**	**183,687**	**-150,888**	**33,469**
Opening balance 2025-01-01		**670**	**183,687**	**-150,888**	**33,469**
New share issues		5,248	36,455	-	41,703
Issue expenses		-	-8,325	-	-8,325
Currency translation differences		-	-	4,185	4,185
Profit/loss for the period		-	-	-44,503	-44,503
Closing balance 2025-12-31		**5,919**	**211,817**	**-191,206**	**26,529**

Equity, cont.

Parent company condensed financial statements

	Restricted equity		Non-restricted equity			
TSEK	**Share capital**	**Other restricted eqity**	**Development fund**	**Premium fund**	**Profit/loss brought forward**	**Total Equity**
Opening balance 2024-01-01	**7,168**	**275**	**14,853**	**176,878**	**-167,978**	**31,196**
Reduction of share capital	-56,942	5,973	-	-	50,969	-
New share issues	50,445	-6,248	-	17,281	-	61,478
Net share issues, subscribed not paid-up	-	13	-	-	-	13
Issue expenses	-	-	-	-10,486	-	-10,486
Development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-41,051	-41,051
Closing balance 2024-12-31	**670**	**13**	**12,996**	**183,674**	**-156,203**	**41,150**
Opening balance 2025-01-01	**670**	**13**	**12,996**	**183,674**	**-156,203**	**41,150**
New share issues	5,248	-13	-	36,468	-	41,703
Issue expenses	-	-	-	-8,325	-	-8,325
Development fund	-	-	-1,857	-	1,857	-
Profit/loss for the period	-	-	-	-	-34,647	-34,647
Closing balance 2025-12-31	**5,919**	**-**	**11,140**	**211,817**	**-188,993**	**39,883**

Disclosure notes

Note 1 Accounting principles

The group's accounting and valuation principles

The annual report and consolidated financial statements have been prepared in accordance with the Annual Accounts Act and the Accounting Standards Board's general guidelines BFNAR 2012:1 Annual report and consolidated statements (K3). The principles are unchanged compared to the previous year.

Consolidated financial statements

In the consolidated financial statements, the parent company and the subsidiaries' operations are consolidated. Subsidiaries are all companies in which the Group has the right to formulate the company's financial and operational strategies in order to obtain financial benefits. The Group obtains and exercises control by holding more than half of the votes. The consolidated financial statements are presented in the currency SEK, which is also the parent company's accounting currency.

Subsidiaries in other countries prepare annual accounts in their respective functional currencies. During the consolidation, the items in these companies' balance sheets and income statements are recalculated to the closing rate and the spot exchange rate for the day the business event in question took place. The exchange rate differences that arise are reported in accumulated exchange rate differences in the group's equity.

Intra-group transactions and balance sheet items are eliminated in their entirety by consolidation, including unrealized gains and losses on transactions between Group companies. In cases where unrealised losses on intra-group assets are reversed through consolidation, the underlying asset's impairment needs are also assessed from a Group perspective.

All amounts in this report have been rounded to the nearest thousand kronor (TSEK) unless otherwise stated. Rounding differences may therefore occur.

Income statement

Net sales include sales of goods and services in the Group's ordinary operations less discounts, value added tax and other taxes directly linked to sales.

Revenues are recognized when it is likely that the financial benefits will accrue to the Group and the revenue can be reliably calculated. Proceeds from the sale of goods are recognised when the material risks and benefits associated with ownership have been transferred to the buyer. Revenue from services is recognized in the period in which the service is performed.

Sales of the company's product are classified as sales of goods and are reported when significant risks and benefits are transferred from the seller to the buyer in accordance with given terms of sale. Sales are reported after deduction of VAT and discounts.

Foreign currencies

Monetary asset and liability items in foreign currency are valued at the closing rate at the balance sheet date. Transactions in foreign currency are converted according to the spot exchange rate on the day of the transaction.

Employee compensation

Compensation to employees refers to all forms of compensation that the company provides to the employees and in the group and consists of salary, social security contributions, holiday pay, paid sick leave, medical care and bonus and compensation after termination of employment (pension). Short-term compensation is reported as an expense and a liability when there is a legal or informal obligation to pay compensation.

The group provides compensation after termination of employment in the form of pensions through defined contribution plans. The group then pays fixed fees to other legal entities that have the commitment towards the employees. The Group has no legal or informal obligations to pay additional fees beyond payments of the established fee that is recognized as an expense in the period in which the relevant service is performed.

Severance pay is paid when the company decides to terminate an employment before the normal time for termination of employment or when an employee accepts an offer of voluntary resignation in exchange for such compensation. If the compensation does not give the company any future financial benefit, a liability and an expense are recognized when the company has a legal or informal obligation to provide such compensation. The compensation is valued at the best estimate of the compensation that would be required to settle the obligation on the balance sheet date.

During the financial year, the company has had no share-based payments.

Lease

Lease agreements are classified at the conclusion of the lease agreement as either financial or operational lease. In the group, there are only operational lease agreements. These are expensed linearly over the lease period.

Loan costs

The loan costs that arise when the Company borrows capital are expensed in the income statement in the period in which they arise.

Income taxes

Total tax consists of current tax and deferred tax. Current tax is income tax for the current financial year which refers to the year's taxable profit and the part of the previous financial year's income tax that has not yet been reported. Deferred tax is income tax for taxable income for future financial years as a result of previous transactions or events.

Current tax, as well as changes in deferred tax, are reported in the income statement unless the tax is attributable to an event or transaction that is reported directly in equity. Tax effects of items that are reported directly against equity are reported against equity.
Current tax is calculated based on the tax rate that applies as of the balance sheet date. Receivables and liabilities are reported net only when there is a legal right to offset.

Deferred tax assets regarding loss carry-forwards or other future tax deductions are reported to the extent that it is deemed likely that the deduction can be deducted against a surplus in future taxation. See note 2.

Intangible assets

Intangible fixed assets are recognized at acquisition value after deductions for accumulated depreciation and impairment. In the consolidated statements, the activation model is applied for internally generated intangible assets.

Depreciation is made on a straight-line basis over the estimated useful life, which for internally generated intangible fixed assets is estimated to be 10 years. Depreciation begins when the asset is ready for use.

External costs for patent applications in new markets are capitalized if the company is deemed to have a financial benefit from the patent in the relevant market. Amortization of capitalized patent costs will take place during the useful life from the time this starts.

Tangible fixed assets

Intangible fixed assets are recognized at acquisition value after deductions for accumulated depreciation. The acquisition value includes expenses that are directly related to the acquisition.

When a component of a fixed asset is replaced, any remaining part of the old component is retired and the cost of the new component is capitalized.

Expenditures for ongoing repair and maintenance are recognized as costs.

Tangible fixed assets are depreciated on a straight-line basis over the asset's estimated useful life. When the depreciable amount of the assets is determined, the asset's residual value is taken into account, if applicable. The company has adopted 5 years as the useful life for all tangible fixed assets.

Impairment testing of intangible and tangible fixed assets

At each balance sheet date, an assessment is made as to whether there is any indication that an asset's value is lower than its reported value. If there is such an indication, the asset's recovery value is calculated. If the recovery value is less than the reported value, an impairment is made and expensed.

An internally developed intangible fixed asset that is not yet ready to be used or sold as of the balance sheet date is always tested for impairment. The recoverable amount of an asset or a cash-generating unit is the higher of fair value less costs to sell and value in use. The net sales value consists of the estimated sales price after deduction of sales costs. The value in use consists of future cash flows.

When assessing the need for impairment, the assets are grouped at the lowest levels where there are separate identifiable future cash flows (cash-generating units).

Write-downs are made if and when the recoverable value is below the carrying amount.

Financial instruments

Financial instruments are valued based on the acquisition value. The instrument is reported in the balance sheet when the company becomes a party to the instrument's contractual terms and includes securities, accounts receivable and other receivables, short-term investments, accounts payable and loan liabilities and any derivative instruments. Financial assets are removed from the balance sheet when the right to receive cash flows from the instrument has expired or been transferred and the Group has transferred substantially all the risks and rewards associated with ownership. Financial liabilities are removed from the balance sheet when the obligations have been settled or otherwise terminated.

Accounts receivable and other current receivables

Accounts receivable and current receivables are recognized as current assets at the amount that is expected to be paid after deduction for individually assessed doubtful debts.

Loan liabilities and accounts payable

Loan liabilities and accounts payable are initially reported at acquisition value after deducting transaction costs. If the reported amount differs from the amount to be repaid at maturity, the difference is accrued as interest expense over the term of the loan using the instrument's effective interest rate. Hereby, at the due date, the recognized amount and the amount to be repaid correspond.

Loan liabilities and accounts payable are initially reported at acquisition value after deducting transaction costs. If the reported amount differs from the amount to be repaid at maturity, the difference is accrued as interest expense over the term of the loan using the instrument's effective interest rate. Hereby, at the due date, the recognized amount and the amount to be repaid correspond.

Set-off of financial receivable and financial debt

A financial asset and a financial liability are set off and recognized at a net amount in the balance sheet only when a legal right to offset exists and when a settlement with a net amount is intended to take place or when a simultaneous disposal of the asset and settlement of the liability is intended to take place.

Impairment testing of financial fixed assets

At each balance sheet date, an assessment is made as to whether there is any indication of impairment in any of the financial fixed assets. Impairment occurs if the decrease in value is deemed to be permanent. The need for impairment is tested individually for shares and other individual financial fixed assets that are significant.

Inventory

Inventory is valued at the lower of acquisition value and net realizable value. The acquisition value is determined using the first-in, first-out principle (FIFU). For raw materials, all expenses that are directly attributable to the acquisition of the goods are included in the acquisition value. For goods in process and finished goods, the acquisition value includes raw materials, direct wages, other direct costs and attributable indirect manufacturing costs.

Cash flow analysis

The cash flow analysis is prepared using the indirect method. The recognized cash flow includes only transactions that entailed receipts or payments. As liquid funds, the company classifies, in addition to cash, as well as short-term liquid investments that are listed on a market place and have a shorter maturity than three months from the time of acquisition. Restricted funds are not classified as liquid funds. Changes in blocked funds are reported in investment activities.

The parent company's accounting and valuation principles

In the parent company, the same accounting and valuation principles are applied as in the group, except in the cases stated below. The principles are unchanged compared to the previous year.

Shares in subsidiaries

Shares in subsidiaries are reported at acquisition value after deduction for any impairment. The acquisition value includes the purchase price paid for the shares as well as acquisition costs. Any capital contributions are added to the acquisition value when they arise. Dividends from subsidiaries are reported as income.

Equity

Equity is divided into restricted and non-restricted equity, in accordance with the division of the Annual Accounts Act.

Note 2 Estimations and assessments

Prostatype Genomics AB makes estimates and assessments about the future. The estimates for accounting purposes that result from these will, by definition, rarely correspond to the actual result. The estimates and assumptions that involve a significant risk of significant adjustments in the reported values of assets and liabilities in the coming years are dealt with in outline below.

Loss carryforward

Prostatype Genomics AB's loss carryforward has not been valued and is not reported as a deferred tax asset. These loss carryforwards are valued only when the company has established a profit level which the company management with certainty considers will lead to tax surpluses.

Intangible assets

The Group's intangible assets consist predominantly of capitalised development costs and, to a lesser extent, licences and other rights.

The accounting of capitalized development costs includes material assessments, primarily regarding when expenses for development projects meet the criteria for capitalization, such as technical and commercial feasibility and the likelihood of future economic benefits.

The management continuously assesses the value of the Group's intangible assets, based on assumptions about future sales growth, operating margins and cash flows. Changes in these assumptions may entail that the reported values need to be reassessed.

In the parent company, additional financing of the subsidiary was expensed on an ongoing basis through write-downs of receivables.

Capital requirements and going concern

The board of directors makes the assessment that the group is dependent on additional capital injections until a positive operating cash flow is reached.

Based on ongoing financing activities, it is the board's assessment that the group will secure the liquidity required for the needs of the business. The board of directors works proactively to secure growth capital through a combination of debt financing, new issues and strategic collaborations to accelerate commercialization. It is the Board's overall conclusion that these measures will ensure continued operations, which is why the report is prepared with the going concern assumption.

However, the board of directors would like to draw attention to the fact that if the necessary additional financing is not realised, this will constitute a material uncertainty factor for the group's ability to continue operations over the next 12 months.

Note 3 Breakdown of sales

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Sweden	285	187	285	187
Europe	197	12	197	12
USA	112	-	-	-
Other	-	-	-	-
	594	199	482	199

There has been no intra-group sales or purchases between the Parent Company and the subsidiary.

Note 4 Remuneration to auditors

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Grant Thornton Sweden AB				
Audit assignment	549	406	549	406
Auditing activities other than auditing assignment	106	218	106	218
Tax consulting	6	-	6	-
	661	**623**	**661**	**623**

Note 5 Average number of employees, salaries and other remuneration

Average number of employees by country	Group		Parent Company	
	2025	2024	2025	2024
Sweden	5	4	5	4
USA	2	2	-	-
	7	**6**	**5**	**4**

Remunerations	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Board and CEO				
Salaries and remuneration	2,527	2,570	2,527	2,570
Statutory Social Security costs	930	929	930	929
Pensions	458	395	458	395
	3,915	**3,894**	**3,915**	**3,894**
Other employees				
Salaries and remuneration	9,771	10,420	3,215	3,807
Statutory Social Security costs	1,108	1,136	1,108	1,136
Pensions	975	568	484	292
	11,855	**12,125**	**4,807**	**5,235**

The CEO is eligible to an annual bonus up to two months's salary worth to the discretion of the Board. If notice is given by the CEO, the period of notice is six months and if notice is given by the company the period of notice is nine months.

Remuneration for the Board has been expensed for the period between the annual general meeting and the end of the period.

Gender distribution in the Board of directors and Executive management

	Group		Parent Company	
	Women	**Men**	**Women**	**Men**
Parent Company				
Board members and CEO	0%	100%	0%	100%
Senior Management	0%	100%	50%	50%
Subsidiaries				
Board members and CEO	0%	100%	0%	100%

Information on gender does not reflect the gender identity of individual employees, but rather the last number in their personal id-number in accordance with gender binary legislation regarding statistics in annual reports.

Note 6 Taxes

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Current tax expense	-	-	-	-
Deferred tax income (+)/expense (–)	-	-	-	-
Current tax	**-**	**-**	**-**	**-**
Net result before taxes	-44,503	-41,051	-34,647	-41,051
Tax calculated according to the Swedish tax rate, 20.6% (20.6%)	9,168	8,457	7,137	8,456
Effect of foreign tax rates	64	49	-	-
Tax effect of non-deductible expenses	-1,310	-2,566	-1,310	-2,566
Tax effect of non-taxable income	71	45	71	45
Tax effect of items presented in equity	1,715	2,160	1,715	2,160
Tax effect of group eliminations	1,262	2,531	-	-
Tax effect of non-capitalized loss carry-forwards	-10,970	-10,675	-7,613	-8,095
Reconciled tax	**-**	**-**	**-**	**-**

Unused and not accounted tax loss carry forwards

The Group's total accumulated tax loss carry forwards on December 31, 2025 amounted to SEK 279 million.

The Parent Company's accumulated tax losses on December 31, 2025 amounted to SEK 244 million.

These tax loss carry forwards does not have any book value since the Group has historically not shown taxable profits.

Note 7 Capitalised development expenditures

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Accumulated acquisition value				
Opening balance	32,160	26,893	27,533	24,286
Investments	13,182	4,939	13,182	3,246
Exchange rate differences	-756	328	-	-
Closing balance	**44,586**	**32,160**	**40,714**	**27,533**
Accumulated amortization				
Opening balance	-5,570	-3,713	-5,570	-3,713
Amortization	-1,857	-1,857	-1,857	-1,857
Exchange rate differences	-	-	-	-
Closing balance	**-7,427**	**-5,570**	**-7,427**	**-5,570**
Net carrying amount	**37,159**	**26,591**	**33,288**	**21,963**

Note 8 Patents

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Accumulated acquisition value				
Opening balance	372	372	372	372
Investments	-	-	-	-
Closing balance	**372**	**372**	**372**	**372**
Accumulated amortization				
Opening balance	-372	-372	-372	-372
Amortization	-	-	-	-
Closing balance	**-372**	**-372**	**-372**	**-372**
Net carrying amount	**0**	**0**	**0**	**0**

Note 9 Licenses

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Accumulated acquisition value				
Opening balance	2,769	-	569	-
Investments	-	2,639	-	569
Exchange rate differences	-359	130	-	-
Closing balance	**2,410**	**2,769**	**569**	**569**
Accumulated depreciation				
Opening balance	-92	-	-9	-
Depreciation	-212	-89	-114	-9
Exchange rate differences	20	-3	-	-
Closing balance	**-284**	**-92**	**-123**	**-9**
Net carrying amount	**2,125**	**2,677**	**446**	**560**

Note 10 Technical equipment

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Accumulated acquisition costs				
Opening balance	710	563	710	563
Investments	67	217	67	217
Divestments	-	-70	-	-70
Closing balance	**776**	**710**	**776**	**710**
Accumulated depreciation				
Opening balance	-462	-503	-462	-503
Depreciation	-67	-29	-67	-29
Divestments	-	70	-	70
Closing balance	**-529**	**-462**	**-529**	**-462**
Net carrying amount	**247**	**247**	**247**	**247**

Note 11 Equipment and tools

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Accumulated acquisition costs				
Opening balance	68	245	68	245
Investments	192	68	192	68
Divestments	-	-245	-	-245
Closing balance	**260**	**68**	**260**	**68**
Accumulated depreciation				
Opening balance	-3	-245	-3	-245
Depreciation	-52	-3	-52	-3
Divestments	-	245	-	245
Closing balance	**-55**	**-3**	**-55**	**-3**
Net carrying amount	**205**	**65**	**205**	**65**

Note 12 Participation in group companies

			Parent Company	
TSEK	**Number of shares**	**Share of capital**	**2025-12-31**	**2024-12-31**
Prostatype Genomics Inc., 6005878, USA	1,000	100%	0	0
			0	**0**

During the year, there have been no changes in the parent company's investments in subsidiaries.

Note 13 Loans to subsidiaries

	Parent Company	
TSEK	**2025**	**2024**
Loans extended	9,507	11,455
Loans repaid	-	-
Currency translation difference	-4,041	1,336
Impairment of loans	-6,126	-12,285
	8,963	**9,623**

The internal loan runs with 10% simple interest.

Note 14 Share capital

	Number of shares		Share Capital, TSEK	
Parent company	**2025**	**2024**	**2025**	**2024**
Number/value at the beginning of the year	6,704,770	119,460,007	670	7,168
New share issues	27,989,347	4,197,126,290	2,799	41,971
Set-off issues	2,306,148	629,240,383	231	6,292
Share issues from warrants excercised	22,189,056	202,524,736	2,219	2025
Reductions of share capital	-	-	-	-56,942
Effect from consolidation of shares 1000:1	-	-5,143,203,065	-	-
Share issues from warrants exercised post-consolidation	-	1,556,419	-	156
Number/value at the end of the year	**59,189,321**	**6,704,770**	**5,919**	**670**

There is only one series of shares. All shares are issued and fully paid in and the terms and conditions of Prostatype Genomics AB's share class are in accordance with Swedish law. As per 31 December 2025, the shares have a quote value of SEK 0.10.

Note 15 Borrowings

	Group		Parent Company	
TSEK	**2025-12-31**	**2024-12-31**	**2025-12-31**	**2024-12-31**
Repayment within 1 year	5,300	67	5,300	67
Repayment in 2–5 years	-	-	-	-
Repayment in more than 5 years	-	-	-	-
	5,300	**67**	**5,300**	**67**
Non-current				
Growth loan, Almi	-	-	-	-
	-	**-**	**-**	**-**
Current				
Growth loan, Almi	-	67	-	67
Bridge loans	-	-	-	-
Shareholder loans	5,300	-	5,300	-
	5,300	**67**	**5,300**	**67**

Note 16 Other current liabilities

	Group		Parent Company	
TSEK	**2025-12-31**	**2024-12-31**	**2025-12-31**	**2024-12-31**
Employee-related liabilities	898	2,646	326	2,646
Accounts payables on payment plan	10,564	-	10,564	-
	11,462	**2,646**	**10,890**	**2,646**

Note 17 Accrued expenses and deferred income

	Group		Parent Company	
TSEK	**2025-12-31**	**2024-12-31**	**2025-12-31**	**2024-12-31**
Employee-related costs	2,905	864	516	864
Accrued interest expenses	795	-	795	-
Other accrued expenses	1,123	2,349	874	2,277
	4,823	**3,213**	**2,186**	**3,141**

Note 18 Adjustments for non-cash items

	Group		Parent Company	
TSEK	**2025**	**2024**	**2025**	**2024**
Depreciations and amortizations	2,187	1,979	2,089	1,899
Adjustment for interest payments	795	-336	-1,101	-1,898
Set-off issues, accounts payable	-	622	-	622
Write-down of loans to subsidiaries	-	-	6,126	12,285
Currency translation effects	4,736	-1,349	3,865	-1,091
	7,719	**916**	**10,979**	**11,817**

Note 19 Pledged assets and contingent liabilities

	Group		Parent Company	
TSEK	**2025-12-31**	**2024-12-31**	**2025-12-31**	**2024-12-31**
Chattel mortgages	-	3,500	-	3,500
Assets with ownership reservation	-	114	-	114
	-	**3,614**	**-**	**3,614**

According to the board's assessment, the company has no contingent liabilities.

Note 20 Transactions with related parties

All transactions with related parties have, in the opinion of the Board of Directors, been conducted on market terms. Other than the transactions described below, no other material transactions with related parties occurred during the financial year.

Shareholder loans

In December 2025 and January 2026, the company signed short-term loan agreements with the board members and major shareholders, among others, of 6.5 MSEK, of which 2.0 MSEK with board members; Håkan Englund with 1.5 MSEK, Anders Lundberg with 0.2 MSEK, Michael Häggman with 0.2 MSEK and Jörgen Dahlström with 0.1 MSEK. The remaining parts were borrowed by shareholders Tobias Wåhlin (2.0 MSEK), Hans Öhman (1.0 MSEK), Lasse Svensson (0.5 MSEK), Anders Liljeblad (0.5 MSEK), Filip Norlin (0.3 MSEK) and Staffan Ek (0.2 MSEK). The loans have a fixed period interest rate of 15% and run until June 30, 2026. The loans were signed privately or through controlled companies.

Consultancy fees

Board member Mattias Prage is employed at Advokatbyrån Lindahl KB, which the company engages for advice on legal issues and company administration. During the year, Lindahl invoiced the company 645 TSEK (1 036).

Board member Jörgen Dahlström is CEO of Mercodia AB, which has purchased consulting services from the company for 145 TSEK (0).

Johan Waldhe, who was a board member up until the 2025 annual general meeting, is CEO of the communications and consulting company Honeybadger AB. Services for 616 TSEK (711) were procured during the time of the board assignment.

Other information

All transactions with related parties have, in the opinion of the Board of Directors, been conducted on market terms. Other than what is stated above, no other material transactions with related parties occured during the financial year.

Note 21 Appropriation of earnings

Retained earnings (SEK) in the parent company at the disposal of the annual general meeting	
Share premium	211,816,929
Retained earnings	-154,346,577
Profit/loss for the year	-34,646,520
	22,823,832
The Board of Directors proposes that the profit/loss be distributed so that they are transferred to the following accounting period.	**22,823,832**

Note 22 Significant events after the end of the financial year

Publication of U.S. validation study

The clinical evidence was further strengthened with the publication of the company's U.S. validation study for Prostatype® in the medical journal Prostate Cancer and Prostatic Diseases. The study, conducted in collaboration with Veteran Affairs and Cedars-Sinai Health System, included a diverse patient population and demonstrated once again that the test demonstrates strong and significant prognostic ability to support clinical decisions in prostate cancer diagnostics. This publication further strengthens the evidence base in the United States and contributes to increased clinical credibility in the most important international market.

Loan financing

In December 2025 and January 2026, the company was provided with additional financial flexibility through the signing of short-term loans totalling 10 MSEK, including loans from both major shareholders and external lenders. The financing aims to secure short-term working capital without an immediate dilution effect for the shareholders.

Proposal for resolution on rights issue

On May 19, 2026, the company announced the board's intention to resolve on a rights issue of units (shares and two series of warrants) of approximately SEK 47.4 million before issue costs. The rights issue is secured to approximately 70 percent through subscription commitments and guarantee commitments and is intended to finance the continued Medicare process and commercialization activities in the US and Europe. Warrants of series TO6 and TO7, if fully exercised, may provide the company with additional capital of a total of approximately SEK 60 million before issue costs.

Management

Fredrik Rickman

Chief Executive Officer since 2017

About: B.Sc in Business Administration and Economics, University of Lund. 30+ years of international life science industry experience in leading positions with focus on operational and organizational growth.

Other assignments: -

Holdings in the Company: 75,035 shares

Steven Gaal

President US operations since 2023

About: BA in Business Administration, East Stroudsburg University. Steven brings over 19 years of successful commercial experience in molecular diagnostics and oncology. Previously, he served as Commercial Director-US of Skyline Diagnostics, a Dutch-owned San Diego based-CAP/CLIA genomics laboratory providing LDT assays for melanoma and multiple myeloma prognosis. At MDxHealth he was instrumental in the launch and clinical adoption of the company's tissue and urine-based LDT tests in urology and oncology. He has also held leadership roles at P4 Diagnostics, was National Director of Sales/ Hospital Pathology at LabCorp/US LABS (acquired by LabCorp).

Other assignments: -

Holdings in the Company: -

Anders Koch

Chief Financial Officer since December 2023

About: M.Sc. in Economics and Business, Stockholm University. Deep experience in financial reporting and managerial finance cemented from 13 years as authorized public accountant with PwC followed by 13+ years as CFO, Financial Controller and member of the Executive Management teams in the Telecom and Digital Media Production industries. The position is part-time.

Other assignments: Carisus Holding AB, CEO and owner

Holdings in the Company: -

The Board of Directors

Anders Lundberg

Chairman of the Board (member of the board since 2017)

About: M.Sc. Mechanical Engineering, KTH, Stockholm, Sweden. Founder and CEO of a telecom equipment supplier recognized by the market and later brought to a successful IPO in 2011 on the MID-CAP list OMX-Nasdaq [TRMO:Transmode]

Other assignments: AJ Lundberg Kapitalförvaltning AB; Board member, Sollentunafastigheter 2 AB; Deputy board member, Sollentunahem AB; Deputy board member

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Holdings in the Company: 606,840 shares

Dr. Michael Häggman

Board member since 2018

About: M.D, Ph.D. associate professor, department of Urology, Akademiska University Hospital, Uppsala, Sweden. More than 30 years of experience practicing as urologist with an extensive national and international network among urologists.

Other assignments: Skrotum Kommanditbolag; General partner, Kardinaltalet AB; Deputy board member

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Holdings in the Company: 456,720 shares

Jörgen Dahlström

Board member since 2013

About: Holds a Ph.D. in Immunology and a M.Sc. in Biochemistry from Uppsala University and an Executive MBA. Jörgen is the CEO of Mercodia, a Swedish based Life Science company and has more than 25 years' experience from the international Life Science industry. The main focus has been on developing and executing company strategies for commercialization and business growth. He has held several senior leadership positions including CEO of Svar Life Science. Jörgen has an extensive strategic and commercial experience and a wide international network.

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Holdings in the Company: 334,000 shares

Mattias Prage

Board member since 2022

About: Lawyer and partner at Advokatfirman Lindahl, specialized in corporate law, financing and commercial contracts.

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Holdings in the Company: -

Håkan Englund

Board member since 2019

About: Various courses in economics and chemistry from Uppsala University, Sweden. Courses in polymer technology at Royal Institute of Technology in Stockholm, Sweden. More than 30 years of operational and investment experience from life science and health care industry with focus on commercialization and business development. Håkan has held several leading management positions at Pharmacia Biotech and Phadia and has during his career developed extensive national and international relevant networks.

Other assignments: Antrad Medical AB; Board member, JDS Invest AB; CEO and owner

Independent in relation to Prostatype Genomics, its senior management and major shareholders.

Holdings in the Company: 1,876,985 shares

Signatures

The Board of Directors and the Chief Executive Officer certify that the annual report and consolidated financial statements for the period 1 January 2025 to 31 December 2025 give a true and fair view of the development of the Group's and the Parent Company's operations, financial position and results of operations, and describe the material risks and uncertainties the Group and the Parent Company are facing.

The annual report and consolidated financial statements were approved for publication by the Board of Directors and the Chief Executive Officer on 1 June 2026.

The annual report and consolidated financial statements were signed by all Board members and the Chief Executive Officer on 1 June 2026.

Anders Lundberg **Chairman of the Board**	**Håkan Englund** **Board member**	**Dr. Michael Häggman** **Board member**
Jörgen Dahlström **Board member**	**Mattias Prage** **Board member**	**Fredrik Rickman** **Chief Executive Officer**

Our audit report has been submitted on June 1, 2026
Grant Thornton Sweden AB

Joakim Söderin
Authorised Public Accountant

Grant Thornton

N.B. The English text is a translation of the official version in Swedish. In the event of any conflict between the Swedish and English version, the Swedish shall prevail.

Auditor's report

To the general meeting of the shareholders of
Prostatype Genomics AB
Corporate identity number 556726 – 0285

Report on the annual accounts and consolidated accounts

Opinions

We have audited the annual accounts and consolidated accounts of Prostatype Genomics AB for the year 2025.

The annual accounts and consolidated accounts of the company are included on pages 13 - 39 in this document.

In our opinion, the annual accounts and consolidated accounts have been prepared in accordance with the Annual Accounts Act and present fairly, in all material respects, the financial position of parent company and the group as of 31 December 2025 and their financial performance and cash flow for the year then ended in accordance with the Annual Accounts Act. The statutory administration report is consistent with the other parts of the annual accounts and consolidated accounts.

We therefore recommend that the general meeting of shareholders adopts the income statement and balance sheet for the parent company and the group.

Basis for Opinions

We conducted our audit in accordance with International Standards on Auditing (ISA and generally accepted auditing standards in Sweden. Our responsibilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Material Uncertainty Related to Going Concern

We draw attention to the text in the Directors' Report under the section Liquidity, financning, capital needs as well as note 2 under the section Capital requirements and going concern which states that the company does not have sufficient working capital to finance its operations in 2025, and that the Board is actively working to resolve the capital requirement. If the outcome of this is not as expected, there is significant uncertainty about the company's ability to continue as a going concern. We would also draw attention to the text in the Valuation of Assets section which states that there is a risk that if the company's objectives are not achieved within the planned timeframe, it may result in the intangible assets being amortised at an accelerated rate, or completely.

Other Information than the annual accounts and consolidated accounts

This document also contains other information than the annual accounts and consolidated accounts and is found on pages 1 - 12. The Board of Directors and the Managing Director are responsible for this other information.

Our opinion on the annual accounts and consolidated accounts does not cover this other information and we do not express any form of assurance conclusion regarding this other information.

In connection with our audit of the annual accounts and consolidated accounts, our responsibility is to read the information identified above and consider whether the information is materially inconsistent with the annual accounts and consolidated accounts. In this procedure we also take into account our knowledge otherwise obtained in the audit and assess whether the information otherwise appears to be materially misstated.

If we, based on the work performed concerning this information, conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors and the Managing Director are responsible for the preparation of the annual accounts and consolidated accounts and that they give a fair presentation in accordance with the Annual Accounts Act. The Board of Directors and the Managing Director are also responsible for such internal control as they determine is necessary to enable the preparation of annual accounts and consolidated accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts and consolidated accounts, The Board of Directors and the Managing Director are responsible for the assessment of the company's and the group's ability to continue as a going concern. They disclose as applicable, matters related to going concern and using

Grant Thornton

the going concern basis of accounting. The going concern basis of accounting is however not applied if the Board of Directors and the Managing Director intend to liquidate the company, to cease operations, or has no realistic alternative but to do so.

Auditor's responsibility

Our objectives are to obtain reasonable assurance about whether the annual accounts and consolidated accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinions. Reasonable assurance is a high level of assur-ance, but is not a guarantee that an audit conducted in accordance with ISAs and generally accepted auditing standards in Sweden will always detect a material mis-state-ment when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these annual accounts and consolidated accounts.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the annual accounts and consolidated accounts, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinions. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of the company's internal con-trol relevant to our audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors and the Managing Director.
- Conclude on the appropriateness of the Board of Directors' and the Managing Director's use of the going concern basis of accounting in preparing the annual accounts and consolidated accounts. We also draw a conclusion, based on the audit evidence obtained, as to whether any material uncertainty exists related to events or conditions that may cast significant doubt on the company's and the group's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts and consolidated accounts or, if such disclosures are inadequate, to modify our opinion about the annual accounts and consolidated accounts. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause a company and a group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the annual accounts and consolidated accounts, including the disclosures, and whether the annual accounts and consolidated accounts represent the underlying transactions and events in a manner that achieves fair presentation.
- Plan and perform the group audit to obtain sufficient and appropriate audit evidence regarding the financial information of the entities or business units within the group as a basis for forming an opinion on the consolidated accounts. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our opinions.

We must inform the Board of Directors of, among other matters, the planned scope and timing of the audit. We must also inform of significant audit findings during our audit, including any significant deficiencies in internal control that we identified.

Report on other legal and regulatory requirements

Opinions

In addition to our audit of the annual accounts and consolidated accounts, we have also audited the administra-tion of the Board of Directors and the Managing Director of Prostatype Genomics AB for the year 2025 and the proposed appropriations of the company's profit or loss.

We recommend to the general meeting of shareholders that the profit be appropriated in accordance with the proposal in the statutory administration report and that the members of the Board of Directors and the Managing Director be discharged from liability for the financial year.

Basis for Opinions

We conducted the audit in accordance with generally accepted auditing standards in Sweden. Our responsi-bilities under those standards are further described in the Auditor's Responsibilities section. We are independent of the parent company and the group in accordance with professional ethics for accountants in Sweden and have otherwise fulfilled our ethical responsibilities in accordance with these requirements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinions.

Grant Thornton

Responsibilities of the Board of Directors and the Managing Director

The Board of Directors is responsible for the proposal for appropriations of the company's profit or loss. At the proposal of a dividend, this includes an assessment of whether the dividend is justifiable considering the requirements which the company's and the group's type of operations, size and risks place on the size of the parent company's and the group's equity, consolidation requirements, liquidity and position in general.

The Board of Directors is responsible for the company's organization and the administration of the company's affairs. This includes among other things continuous assessment of the company's and the group's financial situation and ensur-ing that the company's organization is designed so that the accounting, management of assets and the company's financial affairs otherwise are controlled in a reassuring manner. The Managing Director shall manage the ongoing administration according to the Board of Directors' guidelines and instructions and among other matters take measures that are necessary to fulfill the company's accounting in accordance with law and handle the management of assets in a reassuring manner.

Auditor's responsibility

Our objective concerning the audit of the administration, and thereby our opinion about discharge from liability, is to ob-tain audit evidence to assess with a reasonable degree of assurance whether any member of the Board of Directors or the Managing Director in any material respect:

- has undertaken any action or been guilty of any omission which can give rise to liability to the company, or
- in any other way has acted in contravention of the Companies Act, the Annual Accounts Act or the Articles of Association.

Our objective concerning the audit of the proposed appro-priations of the company's profit or loss, and thereby our opinion about this, is to assess with reasonable degree of assurance whether the proposal is in accordance with the Companies Act.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with generally accepted auditing standards in Sweden will always detect actions or omissions that can give rise to liability to the company, or that the proposed appropria-tions of the company's profit or loss are not in accordance with the Companies Act.

As part of an audit in accordance with generally accepted auditing standards in Sweden, we exercise professional judgment and maintain professional skepticism throughout the audit. The examination of the administration and the proposed appropriations of the company's profit or loss is based primarily on the audit of the accounts. Additional audit procedures performed are based on our professional judgment with starting point in risk and materiality. This means that we focus the examination on such actions, areas and relationships that are material for the operations and where deviations and violations would have particular importance for the company's situation. We examine and test decisions undertaken, support for decisions, actions taken and other circumstances that are relevant to our opinion concerning discharge from liability. As a basis for our opinion on the Board of Directors' proposed appropriations of the company's profit or loss we examined whether the proposal is in accordance with the Companies Act.

Remark

On several occasions during the fiscal year, withheld tax, social security contributions, and value-added tax have not been paid on time. The board has therefore not fulfilled its obligations under the Companies Act, but the omissions have not caused any harm to the company, apart from late payment interest.

Stockholm, according to the date as shown by electronic signature.

Grant Thornton Sweden AB

Joakim Söderin
Authorised Public Accountant

prostatypegenomics.com

prostatype.se